{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:29:43Z","timestamp":1777418983456,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2007,3]]},"abstract":"\n Background:<\/jats:title>\n Coenzyme Q10 (C0Q10) is an endogenous cofactor required for mitochondrial energy production and touted to treat heart failure and prevent statin-induced myopathy. In guinea pig ventricular myocytes, C0Q10 prolongs action potential duration, an effect that might prolong the QTc interval in humans. Additionally, C0Q10 reduced blood pressure in patients with essential hypertension.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n To determine the electrocardiographic (ECG) and hemodynamic impact of C0Q10 in healthy individuals.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Healthy volunteers (N = 26; 62% male, age 24 \u00b1 3 y) were randomized to receive a single dose of C0Q10 50 mg and matching placebo in a crossover fashion with a 7 day washout period between treatments. Twelve-lead ECGs, systolic and diastolic blood pressure, and other hemodynamic parameters (cardiac index and systemic vascular resistance index) were evaluated immediately before (baseline) and 1, 3, 5, and 8 hours after ingestion of the study drug. ECG parameters (P wave and QRS complex duration; PR, QT, QTc, and RR intervals) were measured in lead II by one blinded investigator. For each time point, duplicate blood pressure levels were taken manually and then averaged. Hemodynamic parameters were measured using bioelectrical impedance cardiography.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n C0Q10 had no effect on any of the evaluated ECG parameters. The maximum postdosing systolic blood pressure showed a statistically significant increase with C0Q10 (117 \u00b1 10 vs 119 \u00b1 10 mm Hg; p = 0.037), an effect driven by increases in cardiac index (3.09 vs 2.95 L\/min\/m\n 2<\/jats:sup>\n ; p = 0.017). However, blood pressure elevation was most evident at the 5 hour timepoint (116 \u00b1 10 vs 113 \u00b1 11 mm Hg; p = 0.049) and was only transient. There were no differences between groups for maximum postdosing diastolic blood pressure.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n One dose of CoQ10 does not have any effect on ECG variables and exhibits only mild and transient effect on systolic blood pressure in young, healthy people.<\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1h539","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T21:56:43Z","timestamp":1173218203000},"page":"420-426","source":"Crossref","is-referenced-by-count":6,"title":["Electrocardiographic and Hemodynamic Effects of Coenzyme Q10 in Healthy Individuals: A Double-Blind, Randomized Controlled Trial"],"prefix":"10.1177","volume":"41","author":[{"given":"Sachin A","family":"Shah","sequence":"first","affiliation":[{"name":"University of Connecticut and Hartford Hospital, Hartford, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Sander","sequence":"additional","affiliation":[{"name":"University of Connecticut and Hartford Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Cios","sequence":"additional","affiliation":[{"name":"University of Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Lipeika","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Kluger","sequence":"additional","affiliation":[{"name":"Heart Rhythm Management, Hartford Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C Michael","family":"White","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Connecticut; Director, Cardiovascular Pharmacology Research Group, Hartford Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"bibr1-aph.1H539","volume-title":"Complementary and alternative medicine use among adults: United States, 2002","author":"Barnes PM","year":"2004"},{"key":"bibr2-aph.1H539","volume-title":"Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","author":"Guidance for Industry","year":"2005"},{"key":"bibr3-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.9.797.34564"},{"key":"bibr4-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.10.1541"},{"key":"bibr5-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1177\/1534735405276191"},{"key":"bibr6-aph.1H539","first-page":"131","volume-title":"Biomedical and clinical aspects of coenzyme Q","volume":"5","author":"Arita M","year":"1986"},{"key":"bibr7-aph.1H539","first-page":"493","volume-title":"Biomedical and clinical aspects of coenzyme Q","author":"Takasawa K","year":"1991"},{"key":"bibr8-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.26.52"},{"key":"bibr9-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.5.2460"},{"key":"bibr10-aph.1H539","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc2004.13.6.469"},{"key":"bibr11-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004264167"},{"key":"bibr12-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00426-2"},{"key":"bibr13-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90061-2"},{"key":"bibr14-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A411"},{"key":"bibr15-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520180215"},{"key":"bibr16-aph.1H539","first-page":"493","volume-title":"Biomedical and clinical aspects of coenzyme Q","author":"Gentile S","year":"1991"},{"key":"bibr17-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1007\/BF00226854"},{"key":"bibr18-aph.1H539","first-page":"131","volume-title":"Biomedical and clinical aspects of coenzyme Q","volume":"5","author":"Yamagami T","year":"1986"},{"key":"bibr19-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1002\/biof.5520180211"},{"key":"bibr20-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000057811.86187.88"},{"key":"bibr21-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(97)00042-3"},{"key":"bibr22-aph.1H539","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb01862.x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1H539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1H539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:53Z","timestamp":1777374533000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1H539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1345\/aph.1H539"],"URL":"https:\/\/doi.org\/10.1345\/aph.1h539","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}